Doris Lourdes Asombrado

Doris Asombrado practices at Anaheim Community Hospital in Anaheim, California, part of Signature HealthCARE.

Doris Asombrado's NPI, 1992778666, was assigned on February 10, 2006. Doris Asombrado holds California license 439207.

Doris Asombrado's primary practice is Anaheim Community Hospital, at 3350 W Ball Rd, Anaheim, CA 92804 in Orange County. The practice phone is (248) 905-5091.

Doris Asombrado's primary practice is Anaheim Community Hospital in Anaheim, California, part of Signature HealthCARE. Doris Asombrado is also affiliated with Providence St. Joseph Hospital Orange. The medical group on file is OC Progressive Recovery.

Dmand AI tracks the electronic health record (EHR) system at each site where Doris Asombrado practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Doris Asombrado's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Doris Asombrado is licensed in California.

Dmand AI lists depression among the conditions Doris Asombrado treats.

CMS data shows 72 Medicare services from Doris Asombrado across 2 procedure codes in 2024, for 47 Medicare patients. Medicare paid $4,975 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 47 Medicare patients who saw Doris Asombrado in 2024. The largest group is under 65, with 26 patients. 75% of them have anxiety, and 75% have depression. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Doris Asombrado's median patient age at 42, with 50% women.

In 2024, Doris Asombrado wrote 58 Medicare Part D claims for 22 patients. 88% of them were for generic drugs.

Doris Asombrado accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 29 general payments to Doris Asombrado from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 88% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $893.